Hair loss with GLP-1 drugs is rare, but real, studies find - Reuters
Hair loss with GLP-1 drugs is rare, but real, studies find Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
No locations linked to this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcXhBeVpZSUlKNldpTFN1VlJhNVVhUnN0Uk5QdjNfcER0dFh2NmE1d19BT2p1TUhVY3ppN1hHdlRFeXBIUEVzVmxNa0w1U1dlZWUyanFiVGRPcDcwakh4Yi1yQWpyZDJuTGJ5U2ZWU0hiQzRKZTB4ZE51ZmxmSGZFMHphLTluQzl0QjZKVFQ0Ynh5d2VlcXJTcTA2QnRfa1VBeWpXdU5RMUx6X3lQWS1zazNkTVJ6aktRTDdZRlNoN2lHQQ?oc=5" target="_blank">Hair loss with GLP-1 drugs is rare, but real, studies find</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder Reuters
August 19, 2026 at 10:36 PMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMPrader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026 at 04:25 PMLilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMAs Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
As Hims prepares for peptides launch, Wall Street cautious on prospects this year Reuters
August 12, 2026 at 06:34 PM